Xolair indicated for hives

Share this article:

Genentech's asthma medication Xolair is now indicated for allergic asthma and chronic idiopathic urticaria, aka chronic hives.

The drugmaker announced Monday that the FDA approved the expanded indication, which makes it the first biologic medicine approved for chronic hives.

The approval is limited to patients 12 and older who do not respond to H1 antihistamine therapy. Genentech estimates that about 50% of patients have “an inadequate response” to H1 antihistamine treatment.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.